BioSpace News Archive

Sublicensed stem cell line ESI-053 to ImStem Biotechnology for development of cell therapy candidate IMS001 for COVID-19 and acute respiratory distress syndrome from other causes. Expanded agreement related to ESI clinical-grade pluripotent stem cell lines to provide AgeX independence to sublicense ESI lines to industry and academia for development of cellular therapeutics.

American Bio Medica Corporation announced financial results for the three and nine months ended September 30, 2020 and announced they have applied to up-list its common stock to the OTCQB® Venture Marketplace.

Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), announced today the appointment of Kyung Nam-Wortman as Cellectis’ Executive Vice President, Chief Human Resources Officer. Ms. Nam-Wortman, who will be based in Cellectis’ New York office, is also joining the Company’s executive committee. “Ky is an accomplished

Medexus Pharmaceuticals Inc. (the “ Company ” or “ Medexus ”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) announced its financial and operating results for the three and six months ended September 30, 2020. All dollar amounts below are in Canadian dollars unless specified otherwise. Second quarter fiscal 2021 financial highlights: The Company achieved revenue of $23.6 million for the three-month period ended Septem

Champions Oncology, Inc. (NASDAQ:CSBR), a leading global oncology technology solutions provider that is transforming drug discovery through innovative pharmacology, biomarker and data platforms, announced today the launch of its new proprietary SaaS program known as Lumin Bioinformatics .

Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”) today announced that its Board of Directors has authorized a stock repurchase program under which the Company may purchase up to $10 million of its outstanding common stock through December 31, 2021.

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today reported financial results for the quarter ended September 30, 2020 and provided a business update. Business Highlight s Helomics Magee study completing early in Q4; Helomics presents viable model to Pharma Soluble Biotech moves into new office/lab space tripling capacity; new lab

National Health Investors, Inc. provided a business update regarding its monthly contractual rent collections and average occupancy from its three largest senior housing operators.

64x Bio announced today that they are emerging from stealth and are describing for the first time their proprietary VectorSelectTM platform and vision for the company.

BioLargo, Inc. (OTCQB:BLGO), developer of sustainable technologies and a full-service environmental engineering company, filed with the SEC its Quarterly Report on Form 10-Q for the period ended September 30, 2020 ( www.biolargo.com/sec-filings ). BioLargos Third Quarter Accomplishments Record revenue - generated record revenues in the third quarter, rebounding from early pandemic shutdowns